Evidence map›Paper›PMID 39815775›Full record

ReviewJournal of extracellular vesicles2025

Extracellular RNA communication: A decade of NIH common fund support illuminates exRNA biology.

Sara M Amolegbe, Nicolas C Johnston, Angela Ambrosi, Aniruddha Ganguly, T Kevin Howcroft, Lillian S Kuo, Patricia A Labosky, Dobrila D Rudnicki, John S Satterlee, Danilo A Tagle and 1 more

Abstract readReview
In one paragraph

Review in Journal of extracellular vesicles, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. The Common Fund Data Ecosystem (CFDE).bioRxiv : the preprint server for biology · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sara M AmolegbeOffice of the Director, National Institutes of Health, Bethesda, Maryland, USA.
Nicolas C JohnstonNational Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland, USA.
Angela AmbrosiOffice of the Director, National Institutes of Health, Bethesda, Maryland, USA.
Aniruddha GangulyNational Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
T Kevin HowcroftNational Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Lillian S KuoNational Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Patricia A LaboskyOffice of the Director, National Institutes of Health, Bethesda, Maryland, USA.
Dobrila D RudnickiNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, USA.
John S SatterleeNational Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland, USA.
Danilo A TagleNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, USA.
Christine HappelNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0002-9882-2998

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The discovery that extracellular RNAs (exRNA) can act as endocrine signalling molecules established a novel paradigm in intercellular communication. ExRNAs can be transported, both locally and systemically in virtually all body fluids. In association with an array of carrier vehicles of varying complexity, exRNA can alter target cell phenotype. This highlights the important role secreted exRNAs have in regulating human health and disease. The NIH Common Fund exRNA Communication program was established in 2012 to accelerate and catalyze progress in the exRNA biology field. The program addressed both exRNA and exRNA carriers, and served to generate foundational knowledge for the field from basic exRNA biology to future potential clinical applications as biomarkers and therapeutics. To address scientific challenges, the exRNA Communication program developed novel tools and technologies to isolate exRNA carriers and analyze their cargo. Here, we discuss the outcomes of the NIH Common Fund exRNA Communication program, as well as the evolution of exRNA as a scientific field through the analysis of scientific publications and NIH funding. ExRNA and associated carriers have potential clinical use as biomarkers, diagnostics, and therapeutics. Recent translational applications include exRNA-related technologies repurposed as novel diagnostics in response to the COVID-19 pandemic, the clinical use of extracellular vesicle-based biomarker assays, and exRNA carriers as drug delivery platforms. This comprehensive landscape analysis illustrates how discoveries and innovations in exRNA biology are being translated both into the commercial market and the clinic. Analysis of program outcomes and NIH funding trends demonstrate the impact of this NIH Common Fund program.

Indexed as

Cell CommunicationExtracellular VesiclesRNACOVID-19HumansNational Institutes of Health (U.S.)SARS-CoV-2United StatesRNAexosomeexRNAextracellular RNAextracellular vesicleNIH

Identifiers

PMID39815775
PMCPMC11735951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.